Breast Cancer

Considerations for Treating Patients with CDK4/6 Inhibitors
Considerations for Treating Patients with CDK4/6 Inhibitors
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD
CDK4/6 Inhibitors in Metastatic Breast Cancer
CDK4/6 Inhibitors in Metastatic Breast Cancer
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD
Medically Integrated Pharmacy Teams Spur Innovations
Medically Integrated Pharmacy Teams Spur Innovations
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD
Oral Oncolytics and Patient Adherence
Oral Oncolytics and Patient Adherence
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD
Medically Integrated Dispensing Service Best Practices
Medically Integrated Dispensing Service Best Practices
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD
Practical Challenges in Switching to CDK4/6 Inhibitors
Practical Challenges in Switching to CDK4/6 Inhibitors
BY PANELISTS: JOYCE OSHAUGHNESSY, MD; MICHAEL REFF, RPH, MBA; SARA M. TOLANEY, MD, MPH; LINDSAY SHAW, NP; KATE JEFFERS, PHARMD
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.